Eltrombopag
- Generic Name
- Eltrombopag
- Brand Names
- Promacta, Revolade
- Drug Type
- Small Molecule
- Chemical Formula
- C25H22N4O4
- CAS Number
- 496775-61-2
- Unique Ingredient Identifier
- S56D65XJ9G
- Background
Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also bee...
- Indication
Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction.
- Associated Conditions
- Chronic immune thrombocytopenia, Severe Aplastic Anemia (SAA), Thrombocytopenia
- Associated Therapies
- First-line Therapy
Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation
- First Posted Date
- 2012-12-28
- Last Posted Date
- 2015-06-19
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT01757145
- Locations
- 🇮🇱
Davidof Cancer Center, Beilinson hospital, Rabin medical center, Petach Tikva, Israel
🇮🇱Hadassah hospital, Jerusalem, Israel
Follow-up Study of Patients Who Experienced Thromboembolic Events in the ENABLE Studies
- First Posted Date
- 2012-10-29
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 22
- Registration Number
- NCT01715779
Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia
- Conditions
- Interventions
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 13
- Registration Number
- NCT01703169
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 56
- Registration Number
- NCT01657552
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients
- Conditions
- Interventions
- First Posted Date
- 2012-06-18
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- McMaster University
- Target Recruit Count
- 74
- Registration Number
- NCT01621204
- Locations
- 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada
🇨🇦Sunnybrook Hospital, Toronto, Ontario, Canada
🇨🇦University of Alberta Hospital, Edmonton, Alberta, Canada
Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.
- Conditions
- Interventions
- First Posted Date
- 2012-01-30
- Last Posted Date
- 2015-03-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 92
- Registration Number
- NCT01520909
- Locations
- 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom
Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia
- Conditions
- First Posted Date
- 2011-12-14
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- Duke University
- Target Recruit Count
- 1
- Registration Number
- NCT01491594
- Locations
- 🇺🇸
Duke Cancer Center, Durham, North Carolina, United States
Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma
- First Posted Date
- 2011-12-02
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 1
- Registration Number
- NCT01484314
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- Nordic MDS Group
- Target Recruit Count
- 12
- Registration Number
- NCT01481220
- Locations
- 🇸🇪
4 Locations, Uppsala, Stockholm, Göteborg, Umeå, Sweden
WEUSKOP5410: Observational Study in ENABLE Clinical Trials
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2013-12-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01458080
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.